Collaboration Agreement (Details) $ in Millions |
1 Months Ended | 6 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
|
Nov. 30, 2022
item
|
Jun. 30, 2026
USD ($)
|
Dec. 31, 2025
USD ($)
|
Aug. 06, 2026 |
Jul. 01, 2026 |
|
| LigaChem Biosciences | |||||
| Collaboration Agreements | |||||
| Additional receivable on collaboration agreements, finalization of cost sharing | $ 0.8 | $ 0.4 | |||
| Research Collaboration and Co-Development Agreement | |||||
| Collaboration Agreements | |||||
| Maximum number of antibody drug conjugates to be developed | item | 3 | ||||
| Collaboration agreements cost sharing percentage (as a percent) | 50.00% | 50.00% | 50.00% | ||
| Collaboration arrangement reduction in expenses | $ 0.6 | $ 2.5 | |||
| Research Collaboration and Co-Development Agreement | LigaChem Biosciences | Subsequent Event | |||||
| Collaboration Agreements | |||||
| Collaboration agreements cost sharing percentage (as a percent) | 100.00% | 50.00% |